Mezagitamab
Based on 1 publication(s) in Google Scholar
Mezagitamab (TAK-079) is a IgG1λ anti-CD38 monoclonal antibody. Mezagitamab depletes tumor cells expressing CD38 through antibody and complement dependent cytotoxicity. Mezagitamab has potential application in relapsed/refractory multiple myeloma (RRMM) and idiopathic thrombocytopenic purpura (ITP).
商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。
- 純度: 99.76%
- CAS 番号: 2227490-52-8
- 分子量:143.7 kDa
-
保管条件:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
生物活性
-
化学情報
- 純度とドキュメンテーション
- 参考文献
-
Help & FAQs
MedChemExpress（MCE）の使用を引用している文献 Mezagitamab
More
生物活性
Human IgG1 lambda
Human
CD38
Mezagitamab binds to CD38, allosterically inhibits the enzymatic activity of CD38, induces apoptosis by antibody-dependent cellular cytotoxicity (ADCC, activates immune cells such as NK cells) and complement-dependent cytotoxicity (CDC, activates the complement system)[4].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Mezagitamab (3 mg/kg, iv,once weekly for 8 weeks) prevents collagen-induced arthritis in cynomolgus monkey models[4].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Cynomolgus monkey models[4]
-
Dosage:0.03-100 mg/kg
-
Administration:iv, once or twice a week for 4-13 weeks
-
Result:Reduced numbers of NK/B/T cells.
-
Animal Model:Collagen-induced arthritis in cynomolgus monkey models[4]
-
Dosage:3 mg/kg
-
Administration:iv,once weekly for 8 weeks
-
Result:Inhibited the progression of arthritis.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Unconjugated
The product can be reconstituted/diluted with sterile PBS or saline.
-
Human IgG1 lambda
ELISA, FACS, Functional assay
-
Immobilized CD38 Protein, Human can bind Mezagitamab. The EC50 for this effect is 61.97 ng/mL. -
Flow Cytometry analysis of Raji cells labelling CD38 (red) with Mezagitamab (anti-CD38) (HY-P99730). Goat Anti-Human IgG (Alexa Fluor 488) (HY-P83776) at a dilution of 1/1000 was used as the secondary antibody. Blue-Human IgG1 lambda1 (HY-P99992). Black-Unlabelled control, cells without incubation with primary antibody.
化学情報
-
CAS 番号 2227490-52-8
-
性状 Liquid
-
分子量 143.7 kDa
-
Color Colorless to light yellow
-
SMILES
[Mezagitamab]
-
別名
TAK-079
-
輸送条件
Shipping with dry ice.
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
保管条件
Please store the product under the recommended conditions in the Certificate of Analysis.
Publications (1)
-
Journal Impact Factor
-
Most Recent
純度とドキュメンテーション
-
データシート (261 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Inhibitory Antibodies User Guide (603 KB)
参考文献
[2]. Jadoon Y, et al. Immunotherapy in multiple myeloma. Cancer Treat Res Commun. 2021;29:100468. [Content Brief]
[3]. Kuter DJ. Novel therapies for immune thrombocytopenia. Br J Haematol. 2022 Mar;196(6):1311-1328. [Content Brief]
[4]. Roepcke S, et al., Pharmacokinetics and pharmacodynamics of the cytolytic anti-CD38 human monoclonal antibody TAK-079 in monkey - model assisted preparation for the first in human trial. Pharmacol Res Perspect. 2018 Jun;6(3):e00402. [Content Brief]
[5]. Korver W, et al., A Reduction in B, T, and Natural Killer Cells Expressing CD38 by TAK-079 Inhibits the Induction and Progression of Collagen-Induced Arthritis in Cynomolgus Monkeys. J Pharmacol Exp Ther. 2019 Aug;370(2):182-196. [Content Brief]
Calculators
濃度 (開始) × 体積 (開始) = 濃度 (終了) × 体積 (終了)
Mezagitamab 関連分類
HY-P99730 関連分類
Powered by Bioz